A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

Trial Profile

A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs ASN 002 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Asana BioSciences
  • Most Recent Events

    • 31 Jan 2018 According to an Asana BioSciences media release, data will be presented in the late-breaking session at the annual meeting of the American Association of Dermatology 2018.
    • 04 Jan 2018 Results published in the Asana BioSciences Media Release
    • 28 Dec 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top